MorphoSys' Antibodies by Design and JPT Peptide Technologies Announce Cooperation Agreement.BERLIN & MARTINSRIED/MUNICH, Germany -- Antibodies by Design, a division of MorphoSys AG and JPT JPT Journal of Petroleum Technology JPT Java Power Tools JPT JP Taravella High School (Coral Springs, Florida) JPT Joint Project Team JPT Jet Pipe Temperature (aeronautics) JPT Joint Planning Team Peptide Technologies GmbH, a wholly-owned subsidiary of Jerini AG, today announced the start of a co-marketing agreement between the two specialist companies. Within the scope of this agreement the parties agree to co-market the rapid generation of monoclonal antibodies This is a list of monoclonal antibodies, antibodies which are clones of a single parent cell. When used as medications, the generic names end in -mab (see "Nomenclature of monoclonal antibodies"). by Antibodies by Design and the complementary peptide-based services and products from JPT. Each partner will offer the services of the other to its customers throughout the world-wide market, with exception of Japan. "We are very glad to have reached an agreement with JPT which bears enormous advantages for both companies, and also for our customers", stated Dieter Lingelbach, Head of the Antibodies by Design division and Senior Vice President of MorphoSys AG. "Both companies are absolute specialists in their field and belong to the top addresses for antibody development and innovative peptide-based services in Europe." "MorphoSys' unique antibody repertoire is the ideal complement to our immunology immunology, branch of medicine that studies the response of organisms to foreign substances, e.g., viruses, bacteria, and bacterial toxins (see immunity). Immunologists study the tissues and organs of the immune system (bone marrow, spleen, tonsils, thymus, lymphatic tools program which includes the peptide array platforms PepSpot(TM) and PepStar(TM) plus the novel PepMix(TM) technology for effective T-lymphocyte stimulation. This co-marketing agreement will allow both companies to address new customers and offer them an even wider package of immunology services", said Holger Wenschuh, Managing Director of JPT About JPT Peptide Technologies GmbH JPT Peptide Technologies (www.jpt.com) is a DIN EN ISO (1) See ISO speed. (2) (International Organization for Standardization, Geneva, Switzerland, www.iso.ch) An organization that sets international standards, founded in 1946. The U.S. member body is ANSI. 9001:2000 certified biotechnology company based in Berlin and a leading supplier of innovative peptide-based services and products. JPT is in possession of several proprietary technologies such as the high-throughput peptide synthesis In organic chemistry, peptide synthesis is the creation of peptides, which are organic compounds in which multiple amino acids bind via peptide bonds which are also known as amide bonds. and screening platform PepSpot(TM), the peptide microarray technology PepStar(TM), and PepMix(TM), a unique approach for antigen specific T-cell stimulation by antigen spanning peptide pools. JPT has a world-wide customer base throughout the pharmaceutical and biotechnology industries. JPT is a wholly-owned subsidiary of Jerini AG. About MorphoSys' Antibodies by Design: MorphoSys develops and applies innovative technologies for the production of synthetic antibodies, which accelerate drug discovery and target characterization. Founded in 1992, the Company's proprietary Human Combinatorial Antibody Library (HuCAL(R)) technology is used by researchers worldwide for human antibody generation. The Company currently has licensing and research collaborations with Bayer (Berkeley, California/USA), Boehringer Ingelheim (Ingelheim, Germany), Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were (Wilmington, Delaware/USA), Centocor Inc. (Malvern, Pennsylvania/USA), GPC Biotech GPC Biotech (also referred to as GPCbiotech and GPC-Biotech) is a German biopharmaceutical company. The company's mission statement reads "... to discover, develop and commercialize new anticancer drugs. AG (Munich/Germany), Hoffmann-La Roche AG (Basel/Switzerland), ImmunoGen Inc. (Cambridge, Massachusetts/USA), Novartis AG Novartis AG Swiss pharmaceutical company. It was formed through the 1996 merger of two Swiss firms: Ciba (see Ciba-Geigy) and Sandoz, a chemical company with interests in pharmaceuticals, nutrition, and agriculture. (Basel, Switzerland), Novoplant GmbH (Gatersleben/Germany), Oridis Biomed GmbH (Graz/Austria), Pfizer Inc. (Delaware/USA), ProChon Biotech Ltd. (Rehovot/Israel), Schering AG (Berlin/Germany) and Xoma Ltd. (Berkeley, California/USA). For further information, please visit the corporate website at: http://www.morphosys.com/; information on the Antibodies by Design Division of MorphoSys is available at www.A-by-D.com. Statements included in this press release which are not historical in nature are intended to be, and are hereby identified as, "forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. " for purposes of the safe harbour provided by Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The company cautions readers that forward-looking statements, including without limitation those relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc the company's future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Factors that may affect future operations and business prospects include, but are not limited to, clinical and scientific results and developments concerning corporate collaborations and the company's proprietary rights and other factors described in the prospectus relating to the company's recent public offering. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion